{"name":"Iovance Biotherapeutics, Inc.","slug":"iovance-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Pembrolizumab with Optional Crossover Period","genericName":"Pembrolizumab with Optional Crossover Period","slug":"pembrolizumab-with-optional-crossover-period","indication":"Melanoma (advanced or metastatic)","status":"phase_3"},{"name":"Lifileucel plus Pembrolizumab","genericName":"Lifileucel plus Pembrolizumab","slug":"lifileucel-plus-pembrolizumab","indication":"Metastatic melanoma (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"Pembrolizumab with Optional Crossover Period","genericName":"Pembrolizumab with Optional Crossover Period","slug":"pembrolizumab-with-optional-crossover-period","phase":"phase_3","mechanism":"Pembrolizumab blocks PD-1 on immune cells to release the brakes on anti-tumor immunity, allowing T cells to recognize and attack cancer cells.","indications":["Melanoma (advanced or metastatic)","Non-small cell lung cancer (advanced or metastatic)","Head and neck squamous cell carcinoma","Hodgkin lymphoma (relapsed or refractory)","Urothelial carcinoma (advanced or metastatic)"],"catalyst":""},{"name":"Lifileucel plus Pembrolizumab","genericName":"Lifileucel plus Pembrolizumab","slug":"lifileucel-plus-pembrolizumab","phase":"phase_3","mechanism":"Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy that expands patient-derived T cells from their tumor and reinfuses them alongside pembrolizumab, a PD-1 inhibitor, to enhance anti-tumor immune response.","indications":["Metastatic melanoma (Phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQYmw5SkoxVEYwZldReFJlS0IyLUwxa2hQbUNUa2FMdGNTeTVpTHZmSXNRM3UxeWVaMmRYUU1KNldFU1lGNzBZczdKay1NYzFfb3JFNmtGVmxUT0lSQVh5TjU5V2ducnJ2VzVnb1BiT0lIOW5zbXBBLVk4ZEllRGNwOS1sYVhBRFF2US03WVdpX09ia19iRUlteUg2V2U1NGhHWU1rUllmNFJYYmJleDlMd09PdzBTV1VvSXRDSWdHZmVUQVNBQVJNcENGVWc4NGd2OU5hbTlKd1NWbk1uZmlrVXYwYWRzWXp3cy1HU1lkVW1VWDg2Y1BrdnhibG1ZMnFPYV93bk9WVmpQcFlqME52OHpPRUxoR1RFVlBhMktMazVJU29ZMmdEcTBoMl9FZGhvTm5makctTHNSRTFwSUpr?oc=5","date":"2026-04-03","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and e","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOajB1MHV1YjRkbFNJSllDUEZrN19WQ1hxenoyRE5rWkVzWGk2TzJ5RVNqU2ZuNFNRS3V3UjJ4ZWZ4eFZ6dG5Jb0ZUU1J5V1NZc1huZWFiLVdjZU5XNW9uNVBuNVdQQU5KbW9ZcTVXaUljc3g5cWlwbXdCMGhJSFhBOUVSZmpVbzJ1bE1QLUxwM2pKd2NqU0RZMTNRTHQ3MzcwWWNScmN0dmNWb0tXM1E?oc=5","date":"2026-03-04","type":"pipeline","source":"Seeking Alpha","summary":"Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years - Seeking Alpha","headline":"Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOZDZON3pNd2RvNTNrbll6Z2pHQl9sTTB6eFpZbUp2dk8xN1N3OFN5enMwbWdlcVlNMm04U3VqTG9RaEQ3eXI0eDNRblZwaEpyUFprQ01KVXZkelhVZi1hdkJReDBFVEkwdVcyb0VDeks2c2lURkVXLWRjaGpZUWt2UGNjcUs5QU9TcVRjNl94bXlHbXY2Yjh5STMyMmNQbDhZLUFtNkR4blJTa0M0S1c0S1Z2dy1ndw?oc=5","date":"2025-12-29","type":"pipeline","source":"Seeking Alpha","summary":"Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha","headline":"Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQLU9od1g0ZWxOUWxfcUpRV0VFb185c0JQUTJVOEliclJ1Sm1PNS1EMjFlRDZsUmtBZWo3REdXbUhWWTEzZjFlUEI4RV9jZzNBaEdjeUpTdzRsRmNfclJDZENULVAtS2JuS1ZiS2pqZDh0REt1bnZsLWJXanJFN2k2bjRmUUpkb3R1RjVTMl8zOHVoTzJtaVE?oc=5","date":"2025-11-11","type":"pipeline","source":"The Motley Fool","summary":"Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? - The Motley Fool","headline":"Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQeEJSc0lKOS1RT09MWER6SThmeUVnbUY5M1lMN1VaN0NGeUxXX1pyUExzUWNZUWpIV0QwSzIxQk1fS1BaTjRCQnY3dWFhQ1hjZXpVanFNbzF0NGdQRDQyb01Ia1dGQ1BVa2V1RGQ5T1dTc1U3eGtqc2tJeExaZ1U4SFdfVGlTWkhqVElz?oc=5","date":"2025-11-06","type":"pipeline","source":"timothysykes.com","summary":"Iovance Biotherapeutics Surge: Exploring Recent Developments - timothysykes.com","headline":"Iovance Biotherapeutics Surge: Exploring Recent Developments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPNVVRdHV5NTRzYW5BeG9xMDRsTmpGdEMxN0tlYjF1TWtDemdwUnRhN1MzQ0lyX01jbnZwX3Zaei16dU9HaGR3cjJfYlVscWJQWUFfdXZhWFJDRFA0UTM1cEdXYmZvd3huOHh4TF9sb2pfbHZPenJNVDJFMjBxU0Q2VVVNdzhhamdRaUZvRzZIZGk1LUI5Y2x2TzN2Zw?oc=5","date":"2025-08-07","type":"pipeline","source":"BioPharma Dive","summary":"Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy - BioPharma Dive","headline":"Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPd3I5RE5YNEt5MldBdHMxSzQwdU52Sm1zcWI4N2lkaS1paFRMb3VLNHpMVm1VU0JBbGx6SDVMaHV0Y0Y3RjRLVk5iVHRfWXVvckZ6bUhWQldDbEV2dkp0NVh6M2ZZd1ZQTnRlTVVQd0k0bzhoZVlPaTFWWWYyVXZjRm1CSzJJMUltUHk0dk52bUNiaGI1cU1BZHRlZXp0blF6WGVVUXAtalkycDhOODZqbkNrbjgwY0NzWDFXVUJ2b0dVbndOUkw3MmhSbk5zR09lLXlnMDBjN1c1UnZ2NmxiZmV1ZkRRUVB2eXFyNkNR0gHzAUFVX3lxTE5VX1JzTmY3ZE1SOVhQdEFSWnRKaDJRSmdIeGhNUE9MaFZkR2lHRFloSERNWWtEbU9QUFduVDZMdDRvY09iTjU4UkVoeTg2QU5JajdGeExQdkFzQktjQk1rdFRHZGRiNUd5UW5UTmQ2dXJ6RnhwZlJ2cDVXSnBSM3FEY0RnTnZVSUJ6TGhnUXNfQlVqbER4OVFPSkRVcUUtak9mbk5hVEFBWTlHbldYS0VidVdzemxYWU0wQmJDMEFGWGJSNUNVdHA4TEFEbVVCVW9GOENtQUxWUE1UYXJLckFlV19lc2U4WVRtUnZPR1pLVzNlaw?oc=5","date":"2025-07-22","type":"deal","source":"simplywall.st","summary":"Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st","headline":"Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaWJrZnBVVFpYLW5kdF9pd3ZILVVUSHVRMGJVbzhwemRNNm9VQjBmNGdwZnZ5V3lRaFZkYTNFX3FZUFRMdWlyZnBQSmR2UnVVcGFDZmlVdFdodVd5RUM4bFNta2lhNnZwLTFZejBYNDRpdnFWV0pNSXJMenFKYWI0TUlMVFVkU3lsYzlkRE1IUjZEa3JHSGdLTTdDczNCVTBrY2ZfRWdobTBqdkRSWUE4ajB6QXM3dHdG?oc=5","date":"2025-07-18","type":"regulatory","source":"Seeking Alpha","summary":"Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha","headline":"Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNamg0azdoOTV6WVpISzg5M1hib2R4NXN1U2JMYWFCUHdQcmMyWkJTVzZieWp2aC1WcWVzV29jWWRvSkhMaFdkanA3cHlRM19ZMlUzOGMtdWg2b0tpMnZ4czZ6ZDVVUmt1Z1ZfVC0tbEZkbWJoT2ZKaV9RNkxDTWtOUVd4Y0UyQkN1NUFhU1dkMi1BdUFvUUdFOXVaV0xwRWh0N3NSVDdIX1E2SzFCVDAzdU5UenFLckRCZHd4dW9DVnlET1lhcUpQbkdOWHNWeHBrSDdJN1pUOUtxaVl0NjI0anlSbldVa0o5ZnVkQ0F0YlVLdjJ6M1B6aGZKLUVpZ2FHbXdkYmZxdi1EQ0FyOWtQeTJWcFIxb0hoeFg4M0ZWX2pndGc1TzRRSkxDUQ?oc=5","date":"2025-05-20","type":"pipeline","source":"Business Wire","summary":"IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:IOVA) - Business Wire","headline":"IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPS3ZiU2FkakhubkdqM3pKLVhCd0xHdXFZVzJLQm1hYVJjc1poazByWWpQdUQ2MVl1aVpYMHlpNEFrSGp3U3psWmRsY0tSUzdOTnFwLVU1N3lKeVZGRHlRcXVSNDMzZlBQeGxBRlhuYXNZOV9DeDNCY0xWaVd5Q0ZUSW1hb2dVaUo0Qm1PZQ?oc=5","date":"2025-05-13","type":"deal","source":"Yahoo Finance","summary":"Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance","headline":"Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPTFRoM3RfLXhTdnlvUGF0SWljZDFEMnNYdDZKSndYYWgtd0xLRlpiWGIyREh2aFltMm9yVTFrTE90eXA0NDVMVWlDZWF0OFhKVnJQWXBSMjYza1JxTlBFNDFRLTdObWR6SnpwMm5xRjJQZjE5X0FLYV8wbzlaOXFfcktXMGhYYTVYY3BvTmlVMA?oc=5","date":"2025-05-09","type":"pipeline","source":"Barron's","summary":"Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's","headline":"Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPUlFzOEVTaUxtZDFTQUtGc1d0ZWJiSUtWRjdQYkw2Q2c3ek9hMDNxN3EtMzNuZnZqdTd3R3dMd3cyN193cWkwaFdRY2RkODZMUzZUY1JXT3g4Tm5RNVVBTkRabHRQSl81Tm5RUk1oRmZFcTh6WkVDREJBUkd5YlRZbnB4Zi1YSU9UaWlHR3l5cjZSVGZ4V1g2TmxpV2h4T05qdEVPLTRPUVpZX0dqMlNLeWJwLU1qRVZCV21SNzRYVDFvdEdoaGtKNXdLU1ZCTTZmVG5XN0JCRQ?oc=5","date":"2024-02-16","type":"regulatory","source":"Reuters","summary":"US FDA grants accelerated approval for Iovance's skin cancer cell therapy - Reuters","headline":"US FDA grants accelerated approval for Iovance's skin cancer cell therapy","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}